

31 **ABSTRACT**

32 **BACKGROUND**

33 Point of Care SARS-CoV-2 devices, such as the Abbott ID NOW have great potential, to help
34 combat the COVID-19 pandemic. Starting in December, 2020, the ID NOW was implemented
35 throughout the province of Alberta, Canada (population 4.4 million) in various settings. We
36 aimed to assess the ID NOW performance during the BA.1 Omicron wave and compare it to
37 previous waves.

38 **METHODS**

39 The ID NOW was assessed in two distinct locations among symptomatic individuals: acute care
40 (emergency room, urgent care, and hospitalized patients) and community assessment centres
41 (AC) during the period January 5 – 18, 2022. Starting January 5, Omicron represented >95% of
42 variants detected in our population. For every individual tested, two swabs were collected: one
43 for ID NOW testing and the other for either reverse-transcriptase polymerase chain reaction (RT-
44 PCR) confirmation of negative ID NOW results or for variant testing of positive ID NOW
45 results.

46 **RESULTS**

47 A total of 3,041 paired samples were analyzed (1,139 RT-PCR positive). 1,873 samples were
48 from 42 COVID-19 AC and 1,168 from 69 rural hospitals. ID NOW sensitivity for symptomatic
49 individuals presenting to community AC and patients in hospital was 96.0% [95% confidence
50 interval (CI) 94.5-97.3%, n=830 RT-PCR positive], and 91.6% (95% CI 87.9-94.4%, n=309 RT-
51 PCR positive), respectively. SARS-CoV 2 positivity rate was very high for both populations
52 (44.3% at AC, 26.5% in hospital).

53 **CONCLUSIONS**

54 Sensitivity of ID NOW SARS-CoV-2, compared to RT-PCR, is very high during the BA.1
55 Omicron wave, and is significantly higher when compared to previous SARS-CoV-2 variant
56 waves.

57
58 **Keywords:** ID NOW, COVID-19, SARS-CoV-2, POCT, rapid diagnostics, symptomatic

59

60

61

62

63

64

65

66

67 **INTRODUCTION**

68 The ID NOW (Abbott, Illinois, United States) is approved by the United States Food and Drug
69 Administration (FDA) Emergency Use Authorization for the point of care, rapid detection of
70 severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) in individuals who are within
71 the first 7 days of symptom onset.¹ The ID NOW assay uses isothermal nucleic acid
72 amplification of a region of the viral RNA-dependent RNA polymerase (RdRp) to detect the
73 presence of SARS-CoV-2, with results available in under 15 minutes. Clinical specimens
74 approved by U.S. FDA for testing include nasal, oropharyngeal (OP), and nasopharyngeal swabs
75 (NP), which must be tested on the Abbott ID NOW either immediately or within one hour of
76 collection. Specimens placed in viral/universal transport media (UTM) are not valid for testing
77 by the Abbott ID NOW.¹

78
79 Since December 4, 2020 the ID NOW has been used in various settings throughout Alberta,
80 Canada (4.4 million people). This includes 42 COVID-19 assessment centres and 69 rural
81 hospitals. We previously prospectively evaluated the ID NOW performance among symptomatic
82 individuals in these sites prior to the Omicron variant wave. The clinical sensitivity and
83 specificity of the ID NOW among symptomatic individuals presenting to assessment centres
84 (community swab centres) was 92.5% [95% confidence interval (CI) 92.0-93.0%] and 99.5%
85 (95% CI 99.4-99.5%), respectively (n=70,879 with 10,633 RT-PCR positive). The clinical
86 sensitivity and specificity of the ID NOW among symptomatic individuals in hospital was 89.5%
87 (95% CI 88.3-90.6%) and 99.3% (95% CI 99.2-99.4%), respectively (n=16,924 with 2,932 RT-
88 PCR positive).²

89

90 Currently, there is a paucity of data on the ID NOW performance in the setting of the Omicron
91 variant. Abbott has reported that mutations found in the Omicron variant does not affect the
92 performance based on *in silico* data.³ Due to the different growth kinetics, transmissibility and
93 tissue tropisms than other variants and emergence in a population with 72% vaccination⁴, the
94 performance with Omicron may be different and clinical validation is justified.⁵

95
96 Our aim was to assess ID NOW's clinical performance among symptomatic individuals
97 presenting to assessment centres and patients in emergency rooms and hospitals during a time
98 when the Omicron variant represented the majority of SARS-CoV-2 detected within our
99 population.

100

101 **METHODS**

102 Since December 4, 2020, the ID NOW was gradually implemented across Alberta in the
103 following sites:

104 1) 42 COVID-19 Alberta Health Services (AHS) Public Health assessment/swabbing centres,
105 located in all regions of Alberta: testing of symptomatic individuals and asymptomatic close
106 contacts. These are the primary locations for community patients not needing medical attention
107 to get tested for COVID-19 in Alberta. Testing and swabbing was performed by assessment
108 centre staff (e.g. nurses) within Alberta Precision Laboratories (APL) approved Point of Care
109 Testing (POCT) programs.

110 2) 69 rural hospitals located across Alberta: testing of symptomatic inpatients or ED patients.
111 Swabbing was performed by physicians, nurses, or respiratory therapists. Testing was performed
112 in a College of Physician and Surgeons of Alberta (CPSA) accredited hospital laboratory (APL).

113

114 The collection and testing of COVID-19 samples followed the same procedures as described in
115 our previous paper.² We chose to analyze data from January 5 – 18, 2022, when Omicron
116 represented >95% of SARS-CoV-2 variants detected in our population. Not all individuals with
117 ID NOW positive samples had samples collected for testing of variants of concern, due to
118 changes in our testing protocols designed to conserved lab capacity.

119

120 Individuals were given the option to have POCT by ID NOW and routine testing, or routine
121 testing alone. All individuals tested with the ID NOW had two parallel swabs collected. The first
122 swab collected was either a NP swab or OP swab, which was placed in UTM (Yocon Biology,
123 Beijing, China or GDL Korea Co. Ltd, Seoul, Korea) for RT-PCR, and transported to an
124 accredited laboratory at room temperature and stored at 4°C until processing. The second swab
125 was an OP swab for ID NOW testing (using the OP swab provided in the ID NOW kits). The OP
126 swab for ID NOW testing was always collected second to ensure all individuals had a sample
127 available for RT-PCR (i.e. in case the individual refused the second NP or OP swab). If the ID
128 NOW test was negative, the second swab was sent for confirmatory RT-PCR testing. If the ID
129 NOW test was positive, the second swab was either sent for storage or for variant of concern
130 screening (VoC) testing. All RT-PCR tests sent for variant testing were done within
131 approximately 72 hours from time of collection. During the Omicron wave, only a subset of
132 positive samples were sent for variant testing due to resourcing pressures faced by our
133 laboratory. Positive ID NOW results without subsequent variant testing were considered true
134 positives in this study.

135

136 All RT-PCR testing was performed on the APL Public Health Laboratory E gene PCR or on a
137 Health Canada and FDA approved commercial assay.⁶ Commercial assays were dependent on
138 the testing lab and included the Allplex (Seegene, Seoul, South Korea), BDMax (Becton
139 Dickinson, NJ, United States), Panther (Hologic, MA, United States), GeneXpert SARS-CoV-2
140 or SARS-CoV-2/Influenza/RSV (Cepheid, CA, United States), Cobas 6800 System (Roche
141 Molecular Systems, CA, United States) and Simplexa (DiaSorin, Saluggia, Italy). All samples
142 sent for VoC screening were tested with the ProvLab E gene assay to determine if sufficient viral
143 load was present for VoC testing. E gene RT-PCR results from our lab-developed test were
144 considered positive for SARS-CoV-2 when E gene cycle threshold (Ct) value was <35.
145 If the Ct was ≥ 35 , amplification from the same eluate was repeated in duplicate and was
146 considered positive if at least 2/3 results had a Ct <41.

147

148 All personnel performing the ID NOW swabbing/testing were trained healthcare workers
149 (HCW), who were previously trained in NP and oropharyngeal swab collection. At time of
150 collection, they asked and recorded whether the patient had symptoms or was asymptomatic. All
151 sites and HCW were trained on the ID NOW collection, transport, and testing processes, at least
152 according to the manufacturer's instructions, prior to ID NOW implementation. AHS staff were
153 trained according to the APL POCT program, which meets CPSA accreditation standards. Each
154 ID NOW device underwent a verification process, which included testing 3 positive ID NOW
155 control swabs and 5 negative ID NOW control swabs on the ID NOW instrument before use.
156 One positive control and one negative control swab were tested on the ID NOW instrument after
157 each new box of ID NOW kits was opened, after each new HCW was trained on the instrument,
158 and, after each instrument was transported to a different site.

159 Samples were included for all ID NOW results collected at assessment centres or hospitals
160 among symptomatic individuals. Results without proper documentation of testing location, or
161 without confirmatory RT-PCR, if ID NOW negative, were excluded.

162
163 Data was pulled from our provincial laboratory's centralized electronic database containing
164 SARS-CoV-2 results for all publicly funded testing in the province except for border testing.
165 Sensitivity and specificity of the ID NOW was calculated with Clopper-Pearson 95% confidence
166 intervals. Statistical analysis was performed using Pearson Chi-squared for categorical variables
167 and t-test for continuous variables using STATA (version 14.1).

168
169 The University of Alberta Research Ethics board approved this study (Pro00111835).

171 **RESULTS**

172 A total of 3,498 results were identified between January 5-18, 2022. 457 samples were excluded:
173 35 did not have testing location recorded, 24 did not have an ID NOW result recorded and 398
174 ID NOW negative results did not have parallel RT-PCR results recorded. The remaining 3,041
175 paired samples were analyzed.

176
177 Of the 3,041 paired samples, 1,873 were collected from 42 assessment centres and 1,168 from 69
178 rural hospitals. Baseline characteristics and variant test results of these samples are provided in
179 Table 1. Results, compared to RT-PCR, are provided in Table 2 and Figure 1. In both assessment
180 centres and hospitals, ID NOW positivity rate was extremely high at 44.3% and 26.5%,
181 respectively, and is consistent with SARS-CoV-2 positivity rates observed among other COVID-

182 19 diagnostic platforms during the same time [AHS Surveillance Data]. ID NOW sensitivity was
183 higher among symptomatic individuals presenting to assessment centres (96.0%, 95% CI 94.5-
184 97.3%, n=830 RT-PCR positive) compared to symptomatic patients in hospital (91.6% (95% CI
185 87.9-94.4%, n=309 RT-PCR positive). ID NOW specificity, negative predictive value (NPV),
186 and positive predictive value (PPV) among symptomatic individuals presenting to assessment
187 centres was 97.8% (95% CI 96.7-98.6%), 96.9% (95% CI 95.7-97.7%), and 97.2% (95.9-98.1%),
188 respectively. ID NOW specificity, NPV, and PPV among symptomatic individuals in hospital
189 was 98.6% (95% CI 97.6-99.3%), 97.0% (95.8-97.9%), and 95.9% (93.1-97.6%), respectively.

190

191 E gene Ct values for ID NOW true positive and true negative results are provided in Table 1.

192 Mean E gene Ct values were higher among ID NOW false negatives compared to true positives,
193 but were only statistically significant for hospital patients ($p < 0.001$).

194

195 **DISCUSSION**

196 Use of point of care SARS-CoV-2 tests, such as the ID NOW, for the detection of SARS-CoV-2
197 among individuals remains a worthwhile endeavour. At time of writing, this is the first study to
198 evaluate the ID NOW during the Omicron variant wave. In the face of Omicron, our study
199 demonstrated increased ID NOW sensitivity compared to prior variant waves.² The ID NOW
200 sensitivity in assessment centres before Omicron (as of November 24, 2021) was 92.5% (95% CI
201 92.0-93.0%). Our current data during the Omicron wave has demonstrated a higher ID NOW
202 sensitivity of 96.0% (95% CI 94.5-97.3%). Sensitivity in hospital settings also increased with the
203 Omicron wave, though the difference was not statistically significant (pre-Omicron it was
204 89.5%, 95% CI 88.3-90.6%, compared to 91.6% during Omicron, 95% CI 87.9-94.4%). In

205 response to this study and the high sensitivity in previous waves, our provincial laboratory no
206 longer requires confirmation of negative ID NOW results when tested on symptomatic
207 individuals presenting to community assessment centres within 7 days of symptom onset.

208

209 In the current Omicron study and our previous ID NOW study, sensitivity was slightly lower in
210 hospital settings compared to community assessment centres. However, its performance was still
211 higher for Omicron than what we previously observed, but not statistically significant (likely due
212 to the lower sample size in our Omicron study).² There may be various factors to account for the
213 decreased ID NOW sensitivity observed among hospitals compared to assessment centres.

214 Firstly, ID NOW testing is performed immediately after sample collection at assessment centres,
215 whereas hospitals require transportation to the on-site lab prior to ID NOW testing. While ID
216 NOW testing was mandated to be done within 1 hour from collection, short periods of time from
217 transportation may potentially affect performance.⁷ Secondly, a higher proportion of individuals
218 with lower viral loads may be tested in emergency rooms, as a result of patients commonly
219 presenting to hospital later in their symptom onset course, which is associated with higher
220 SARS-CoV-2 E gene Ct values.^{8,9} Symptomatic individuals presenting to assessment centres, in
221 comparison, are often within the first few days of symptom onset, but because it generally takes
222 approximately 24 hours to arrange a booking, are not at the very beginning of their symptom
223 onset.

224

225 Why ID NOW sensitivity improved in the face of Omicron is not fully known. There have been
226 reports that the SARS-CoV-2 viral loads observed among clinical specimens with the Omicron
227 variant are not different from clinical specimens of other variants.^{10,11} There are suggestions that

228 Omicron has altered tissue tropism compared to prior variants which may make sampling from
229 the oropharynx more reliable.¹² Higher COVID-19 prevalence during the Omicron wave could
230 have also contributed. Positivity rate for all COVID-19 tests done during the study period in
231 Alberta was 36.74% compared to 4.27% and 9.09% during the wild type peaks (April 2020 and
232 December 2020), 13.56 for alpha (May 2021), and 13.47% for Delta (September 2021) [AHS
233 surveillance dashboard].

234

235 Interestingly, a high proportion (87.0%) of the false positives detected in our study, among
236 individuals at assessment centres, were from samples collected using a nasopharyngeal swab.
237 Due to the many (45.5%) ID NOW positive samples that were subsequently not tested for
238 variants in our study, the specificity calculated in our study is likely even lower. The reasons
239 behind reduced specificity is unclear, but potentially related to altered tissue tropism favouring
240 samples from the oropharynx over the nasopharynx when tested earlier in the COVID-19
241 infection course.¹³ Lower specificity is unlikely to be explained by other factors, such as SARS-
242 CoV-2 contamination, given that our testing was conducted across over 100 sites and there has
243 not been prior reports of contamination or high rates of false positive results with the ID NOW in
244 the literature.

245

246 Strengths of this study include the large sample size studied in various real-world locations,
247 including community COVID-19 assessment centres and hospitals. Due to the same testing sites,
248 procedures, and methodology, the results during Omicron can be accurately compared to our
249 results from before Omicron.² Due to the routine surveillance testing of many positive ID NOW
250 or RT-PCR samples for variants of concern, which included E gene RT-PCR from a consistent

251 RT-PCR testing platform (APL LDT), we were able to roughly assess the specificity of the ID
252 NOW and examine the relationship of E gene Ct values between true positive and false negative
253 ID NOW results in the face of Omicron.

254

255 Our study had several limitations. Due to the heterogeneity of our populations tested, it is
256 difficult to exclude confounders that may have contributed to ID NOW performance. However,
257 we previously observed no differences in sensitivity based on common patient, collecting and
258 testing characteristics, including age, gender, and swab type.² Our current study also did not
259 demonstrate any difference in performance with these characteristics, though the sample size was
260 not large enough to make any concrete conclusions. Another limitation is the inability to
261 exclusively study Omicron by itself. While the Delta variant only represented 0.7% of variants
262 detected from the assessment centres during our study period, there was still a moderately high
263 proportion (14.5%) of delta variant still circulating within our hospitals. This study did not assess
264 the Omicron BA.2 sublineage, as it was not circulating in our population during the study period.

265

266 Other limitations include missing parallel RT-PCR results that could affect the sensitivity
267 observed in our study. As previously mentioned, many (45.5%) ID NOW positive samples did
268 not undergo variant testing which would affect our calculated specificity. ID NOW sensitivity
269 may be slightly lower than we calculated due to the exclusion of 398 ID NOW negative samples
270 that subsequently did not have a second sample tested with RT-PCR. Reasons behind missing
271 parallel RT-PCR are multifactorial and include sample lost or discarded prior to testing, testing
272 sites going against guidelines and not obtaining a second swab for RT-PCR confirmation, and

273 patient demographic mismatches resulting in test cancellation or inability to match ID NOW and
274 RT-PCR tests together in our electronic database.

275

276 In conclusion, the performance of the ID NOW improved in sensitivity during the Omicron BA.1
277 wave. Reasons for improved sensitivity may potentially be related to increased COVID-19
278 prevalence and/or altered tissue tropism favouring the oropharynx early in the COVID-19
279 infection course. More research is required to prove this claim.

280

281 **Acknowledgments**

282 This work was funded using internal operating funds of Alberta Precision Laboratories and
283 Alberta Health Services (AHS). Test kits and instruments were paid for by the Public Health
284 Agency of Canada. We thank staff at AHS assessment centre and contracted mobile teams for
285 collecting and testing samples in the community, and Alberta Precision Laboratory staff for
286 assistance with testing of samples, and in the development and support of the various testing
287 programs.

288

289 **Declarations**

290 *Funding:* Internal funding from Alberta Precision Laboratories and Alberta Health Services.

291 *Conflict of Interest:* The manufacturer had no role to play in the study. The authors have no
292 conflict of interests to disclose pertaining to this study.

293 *Availability of data:* Available upon request.

294

295

296

297

298 **REFERENCES**

- 299 1. United States Food and Drug Administration. ID NOW COVID-19 – instructions for use.
300 2020. [Accessed Feb 10, 2022]. Available from:
301 <https://www.fda.gov/media/136525/download>
- 302 2. Stokes W, Venner AA, Buss E, Tipples G, Berenger BM. Then and NOW: a prospective
303 population-level validation of the Abbott ID NOW SARS-CoV-2 device implemented in
304 multiple settings for testing asymptomatic and symptomatic individuals. *MedRxiv*
305 2022.04.30.22274189; doi:<https://doi.org/10.1101/2022.04.30.22274189>
- 306 3. Abbott. Evaluating Omicron and other COVID variants to ensure test effectiveness.
307 [Accessed Feb 27, 2022]. Available from:
308 [https://www.abbott.com/corpnewsroom/diagnostics-testing/monitoring-covid-variants-to-](https://www.abbott.com/corpnewsroom/diagnostics-testing/monitoring-covid-variants-to-ensure-test-effectiveness.html)
309 [ensure-test-effectiveness.html](https://www.abbott.com/corpnewsroom/diagnostics-testing/monitoring-covid-variants-to-ensure-test-effectiveness.html)
- 310 4. Government of Alberta. 2022. [Accessed Feb 27, 2022]. Available from:
311 <https://www.alberta.ca/stats/covid-19-alberta-statistics.htm>
- 312 5. Zhao H, Lu L, Peng Z, et al. SARS-CoV-2 Omicron variant shows less efficient
313 replication and fusion activity when compared with Delta variant in TMPRSS2-expressed
314 cells. *Emerg Microbes Infect.* 2022;11(1):277-283.
- 315 6. Pabbaraju, et al. Development and validation of reverse transcriptase-PCR assays for the
316 testing of SARS-CoV-2. *JAMMI.* 2020. Doi:10.3138/jammi-2020-0026: e20200026
- 317 7. Stokes W, Berenger BM, Singh T, et al. Acceptable performance of the Abbott ID NOW
318 among symptomatic individuals with confirmed COVID-19. *J Med Microbiol.*
319 2021;70(7):001372. PMID: 34309503.
- 320 8. Stokes W, Kanji JN, Hu J, Zelyas N, Berenger BM. Wide variation in threshold cycle
321 values clouds the interpretation of SARS-CoV-2 infectiousness. *Clin Chem.*
322 2021;68(1):253-255.
- 323 9. Peacock WF, Soto-Ruiz KM, House SL, et al. Utility of COVID-19 antigen testing in the
324 emergency department. *J Am Coll Emerg Physicians Open.* 2022 Jan 15;3(1):e12605.
- 325 10. Hay JA, Kissler SM, Fauver JR, et al. Viral dynamics and duration of PCR positivity of
326 the SARS-CoV-2 Omicron variant.
327 *medRxiv* 2022.01.13.22269257; doi:<https://doi.org/10.1101/2022.01.13.22269257>
- 328 11. Puhach O, Adea K, Hulo N, et al. Infectious viral load in unvaccinated and vaccinated
329 patients infected with SARS-CoV-2 WT, Delta and Omicron.
330 *medRxiv* 2022.01.10.22269010; doi:<https://doi.org/10.1101/2022.01.10.22269010>
- 331 12. Marais G, Hsiao N, Iranzadeh A, et al. Saliva swabs are the preferred sample for
332 Omicron detection.
333 *medRxiv* 2021.12.22.21268246; doi:<https://doi.org/10.1101/2021.12.22.21268246>
- 334 13. Adamson B, Sikka R, Wyllie AL, Premrurit P. Discordant SARS-CoV-2 PCR and rapid
335 antigen test results when infectious: A December 2021 occupational case series. *medRxiv*
336 2022.01.04.22268770. <https://doi.org/10.1101/2022.01.04.22268770>

337
338
339
340
341
342
343

344
 345
 346
 347
 348
 349
 350
 351
 352
 353
 354
 355
 356
 357
 358
 359
 360
 361
 362

Table 1: Characteristics between individuals tested with ID NOW SARS-CoV-2

Site	Assessment centre	Hospital
Mean age (median, range)	38.6 (38.0, 0.5-85.8)	51.3 (55.2, 0.09-103.2)
Male gender	33.1%	48.8%
NP swab used for parallel RT-PCR testing* (%)	78.3%	92.1%
Variant** (%)	Omicron (89.3%) Delta (0.7%) Unresolved (10.0%)	Omicron (70.4%) Delta (14.5%) Unresolved (15.0%)
Mean E gene Ct value from variant testing of true positives (median, range)	22.7 (21.6, 14.5-40.9)	22.6 (21.5,15.2-38.1)
Mean E gene Ct value from variant testing of false negatives (median, range)	25.8 (25.4, 21.6-34.5)	32.1 (34.1, 17.1-36.7)

363
 364
 365
 366
 367
 368
 369
 370
 371
 372
 373
 374
 375
 376

NP: nasopharyngeal

Ct: Cycle threshold

*Either NP or oropharyngeal swab was used for parallel RT-PCR testing. In hospitalized patients, a minority of samples were other specimen types such as endotracheal tube aspirates.


**n=428 for assessment centres, n=193 for hospital

377 Table 2: Performance of ID NOW, compared to RT-PCR, using oropharyngeal swabs.
 378

Assessment Centre			
		RT-PCR	
		Positive	Negative
ID NOW	Positive	797	23
	Negative	33	1020
Hospital			
		RT-PCR	
		Positive	Negative
ID NOW	Positive	283	12
	Negative	26	847

379
 380
 381
 382
 383
 384
 385
 386
 387
 388

Figure 1: Sensitivity and specificity of ID NOW (oropharyngeal swab) compared to RT-PCR (oropharyngeal swab or nasopharyngeal swab). Error bars represent 95% confidence intervals. AC = assessment centre.



389
 390